Good News from the NIH/NIAID-sponsored Phase 2 Clinical Trial of BiondVax’s M-001 Universal Influenza Vaccine Candidate
Preliminary Data from NIH/NIAID-sponsored Phase 2 Clinical Trial of BiondVax’s M-001 Universal Influenza Vaccine Candidate Validates Results of Previous Clinical Trials Data published on Clinicaltrials.gov
Successful BrainsWay Pivotal Multicenter Study Evaluating Deep Transcranial Magnetic Stimulation System as Smoking Cessation Aid
BrainsWay Ltd. achieved final positive results from its pivotal multicenter trial on the safety and efficacy of the Company’s H4 Deep transcranial magnetic stimulation system
Finally, a Pill that Could Fix the Cause of Type2 Diabetes
Zygosid-50, a drug under development in Israel, could be the first to treat type 2 diabetes by restoring the body’s insulin sensitivity, without side effects.
Augmedics Announces U.S. Launch of xvision, First Augmented Reality Surgery Guidance System
Augmedics, a pioneer in augmented reality surgical image guidance, has announced U.S. Food and Drug Administration (FDA) 510(k) clearance and the U.S. launch of its
Novelstem Increases Newstem Ownership to 27.3%
Following achievement of an important milestone for Stem-Cell based cancer treatments resistance diagnostics, Jerusalem based NewStem received a further $ 1 million follow-on investment from
Fat Melting Pharmaceutical Company Raziel Therapeutics Raises $22 Million
Raziel Therapeutics a clinical-stage pharmaceutical company announces a $22 million Series C preferred stock financing led by Pontifax, with the participation of existing investors Dr. Shmuel Cabilly
Concenter Biopharma Ltd. is developing a Promising Drug for Treating and Preventing Type 2 Diabetes (T2D)
Concenter Biopharma is working on a novel drug to eliminate type 2 diabetes with no side effects. The drug dramatically lowers insulin resistance, the major
SaliStick of Salignostics-the World’s First Saliva Rapid Pregnancy Test at Medica Expo, Germany
During the MEDICA exhibition in Düsseldorf, Germany, on November 18, Salignostics present for the first time the world’s first saliva rapid pregnancy test, the SaliStick. Salistick provides
Entera Bio recently entered into a $270 million license agreement with Amgen
Entera Bio‘s platform technology enables oral therapies based on molecules that would otherwise undergo gastric degradation and have limited or no bioavailability. By transforming injectable